Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Payables (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Payables for 6 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • Quarterly Payables fell 79.17% to $3.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Dec 2025, down 79.17% year-over-year, with the annual reading at $3.1 million for FY2025, 79.17% down from the prior year.
  • Payables for Q4 2025 was $3.1 million at Lexicon Pharmaceuticals, down from $3.8 million in the prior quarter.
  • The five-year high for Payables was $14.8 million in Q4 2024, with the low at $3.1 million in Q4 2025.
  • Average Payables over 3 years is $10.0 million, with a median of $10.6 million recorded in 2023.
  • Peak annual rise in Payables hit 32.5% in 2025, while the deepest fall reached 79.17% in 2025.
  • Over 3 years, Payables stood at $14.4 million in 2023, then grew by 2.86% to $14.8 million in 2024, then plummeted by 79.17% to $3.1 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $3.1 million, $3.8 million, and $5.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.